SRRA stock: buy or sell?
May 15th, 2020
Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally.
Should I buy SRRA stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Sierra Oncology stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Sierra Oncology stock a buy?
Banks and financial institutions post stock ratings everyday.Unfortunately, we couldn't detect any rating for SRRA stock for the last 30 days.
SRRA stock analysis
Sierra Oncology shares boosted 6.51% to $12.10 today.
Sierra Oncology boosted an exceptional 6.51% and closed at $12.10.
Sierra Oncology remained constant a tight 0.25% this week. Late March SRRA plummed a chilling -14.24% in just one week. Late April SRRA boosted a super good 7.13% in just one week.
SRRA stock price history
SRRA IPO was on July 16th, 2015 at $1,147.20 per share1. Since then, SRRA stock lost a -98.90%, with a yearly average of -24.70%.
1: Adjusted price after possible price splits or reverse-splits.
SRRA stock historical price chart
SRRA stock reached 52-week highs at $62.40, and all-time highs 2015-07-16 with a price of 1350.
SRRA stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' SRRA stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not detected any price target for Sierra Oncology stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per Share, Sierra Oncology failed to meet the estimates of the analysts and reported a rough EPS of $-0.19 per share when experts were expecting $-0.21.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn , Sierra Oncology annual sales to million dollars from marked in . When comparing vs , , profit margin (that is, the net income divided by revenues) a to .
Quarterly financial resultsReported quarter income marked $-14.28 M with a profit margin of . Profit margin remained constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing turnover to same quarter last year, Sierra Oncology sales marked a tight move and stayed constant a nan%. Looking back to recent quarterly results, Sierra Oncology posted 7 negative quarters in a row.
Sierra Oncology ownershipReviewing Sierra Oncology ownership structure gives valuable information about the company and its governance (insider ownership) or the amount of investors that are on the short side.
Sierra Oncology shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 3.42% of all shares.
In case of Sierra Oncology stock, 57.14% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for SRRA stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Sierra Oncology:
|Market cap||$125.8 M|
|Total shares||10.4 M|
|Float shares||3.3 M|
|- Institutional holdings (%)||57.1%|
|- Insider holdings (%)||3.4%|
|Shares in short selling||0.0%|
|Friday, May 15th, 2020|
|Day range||$11.65 - $12.35|
|Average true range||$1.06|
|50d mov avg||$10.88|
|100d mov avg||$12.54|
|200d mov avg||$13.75|
Sierra Oncology performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We picked as the bechmarking frame for Sierra Oncology stock.